Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,431–1,440 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1431
- Medicine slug
- sulfasalazine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
7.6 ± 3.4 hrs
- Numeric value
- 7.6
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:257cee60-b68f-4c2b-b57d-8e4d73d17e09 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9ef541a-93c8-4428-ba45-398aa0b327d1 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32fd1726-ed81-4441-9594-3aecf2db1dbf (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d596ac59-b643-4181-80ba-f2db1cc3459c (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hrs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88441a9f-b4f9-455d-a355-46fb30699a7b (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3254432e-87a4-4af0-afd1-d9e6f1b0efd4 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf5137fe-60ed-4497-8521-eeb0a684fabf (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76b532a3-e7ca-4929-8c51-c0f66e0806a8 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a54b31cc-205d-43d3-a850-acf4b41fbc37 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:029716bd-ee1a-484c-bf1f-ec8d02d5281b (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:618c5324-d0a6-4d00-9b12-0de88a71c180 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c59593b-e1a5-47cb-a82b-3e5e49205344 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48fbc535-a33a-45ee-85ff-9d1ec9b31d9c (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbe69f3-bd55-45f3-a64f-f60226c744c4 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.
Projected row 1432
- Medicine slug
- sulfasalazine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:257cee60-b68f-4c2b-b57d-8e4d73d17e09 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9ef541a-93c8-4428-ba45-398aa0b327d1 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32fd1726-ed81-4441-9594-3aecf2db1dbf (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d596ac59-b643-4181-80ba-f2db1cc3459c (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88441a9f-b4f9-455d-a355-46fb30699a7b (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3254432e-87a4-4af0-afd1-d9e6f1b0efd4 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 μg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf5137fe-60ed-4497-8521-eeb0a684fabf (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76b532a3-e7ca-4929-8c51-c0f66e0806a8 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a54b31cc-205d-43d3-a850-acf4b41fbc37 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:029716bd-ee1a-484c-bf1f-ec8d02d5281b (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 μg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:618c5324-d0a6-4d00-9b12-0de88a71c180 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 mcg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c59593b-e1a5-47cb-a82b-3e5e49205344 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 mcg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48fbc535-a33a-45ee-85ff-9d1ec9b31d9c (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbe69f3-bd55-45f3-a64f-f60226c744c4 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 µg/mL) occurring at 6 hours.
Projected row 1433
- Medicine slug
- sulfasalazine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
7.5 ± 1.6 L
- Numeric value
- 7.5
- Unit
- L
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:257cee60-b68f-4c2b-b57d-8e4d73d17e09 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9ef541a-93c8-4428-ba45-398aa0b327d1 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32fd1726-ed81-4441-9594-3aecf2db1dbf (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d596ac59-b643-4181-80ba-f2db1cc3459c (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88441a9f-b4f9-455d-a355-46fb30699a7b (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3254432e-87a4-4af0-afd1-d9e6f1b0efd4 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf5137fe-60ed-4497-8521-eeb0a684fabf (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76b532a3-e7ca-4929-8c51-c0f66e0806a8 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a54b31cc-205d-43d3-a850-acf4b41fbc37 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:029716bd-ee1a-484c-bf1f-ec8d02d5281b (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:618c5324-d0a6-4d00-9b12-0de88a71c180 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c59593b-e1a5-47cb-a82b-3e5e49205344 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48fbc535-a33a-45ee-85ff-9d1ec9b31d9c (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution: Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbe69f3-bd55-45f3-a64f-f60226c744c4 (opens source in a new tab)
Sulfasalazine label
Version not recorded · Effective date not recorded
Distribution Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L.
Projected row 1434
- Medicine slug
- sumatriptan
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 87
- Source count
- 59
- Agreement rate
- 0.847458
- Recorded readings
15%
- Numeric value
- 15
- Unit
- %
- Source records
- 50
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 50 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9485cc30-15e8-4b53-876d-db317145474b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85bf8e58-0984-427b-9ed4-7e0df4e444d2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68daf82a-334e-43ca-b4bb-5c66a82f52c8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cba3661-9b16-416b-b0c0-bbb12549d48f (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27ca3c0-9de0-ff9c-e053-2a95a90ab894 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:082d05f6-3850-0fa2-e063-6294a90a0c66 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2efd4269-5657-9669-e063-6394a90a583a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e90b0eea-c424-4f00-98da-6ed6e80de1f6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abbd2168-1523-4eb6-a75c-dc4d7d1b1c9b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2e7d756-1e12-462a-a43f-a9d860b11ee8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf9fd9fe-095b-4478-bd2e-a5534af07761 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352d2ab3-d2c7-48c8-bcd4-d46ed9bdfa85 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac80d018-6abf-2e41-ddea-90b4ff9e9013 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584abe73-8290-4484-ff8e-5890831c095e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:121e36fb-471b-4318-bc47-b087ad68c6f7 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1042b91c-715c-4e90-b9cc-d91a17f9f7cb (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aab8786-b225-833a-e063-6394a90ac7ae (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84bfc4ba-4172-4adb-b963-4e0eb438c07a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8c4bbfb-1586-4610-e053-6394a90a8f09 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c87cf537-9f7f-400e-ac4b-86e6f7e78775 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62ba6fef-467a-4500-993c-51907f12a67c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d1f3de0-684a-4092-be30-aa325ff20d04 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d556563f-ad71-45c1-829a-cc11983bce0c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97016a59-3b49-4134-85aa-8c866f285601 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b297a466-7d24-9ebd-e053-2a95a90af4d1 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:284ee7ac-759e-b592-e063-6394a90a78ba (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff08b9ee-03bf-4f5b-930e-233a3b8866af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77f9f135-e840-48f0-81e8-73e08433e768 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baf37e8c-d414-4ca7-a366-97dc202372ff (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efb7ec4e-0a5d-2aae-e053-2a95a90aebf2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c907a3-9624-f893-e053-6294a90a31af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2503fff-c978-4efa-b1b4-d7740b6b26f2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d071aef6-a5bd-4f68-ba6d-03004466897c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a118cf-2179-572a-e053-2995a90acbb0 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85295be9-852d-4e21-e053-2991aa0a8a78 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da77dfc4-551c-4e0e-a65e-cb478f193cd9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d2cd01c-05e7-44cf-a71d-0f474e826b7e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73c9ac06-b55e-41e0-90ec-deb250f37eb5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9c78ac5-7328-4204-8f66-96606d7db5c3 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c95873-576d-a1c2-e053-6294a90a3ff9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f4d487a-c5f7-4707-976b-64e738c98d45 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe09fab6-b9e3-469c-9a38-bcc343dcc899 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:790acc89-81b3-4869-92e7-dc9f7fa6567b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b9a0ab5-d8bd-4cae-b86c-45740ee1015a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bf70380-8272-4c0d-8841-d39ef2772351 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a41cca-02d2-4b84-975e-d1925f0fca80 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b16886d0-224b-4d83-85c4-bc3eb3606c17 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54c6f8f4-5466-3988-e054-00144ff8d46c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a96f37d-03f6-678c-e063-6394a90ae0c6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7628caf4-5272-4e42-e053-2a91aa0a2f24 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The bioavailability is approximately 15%, primarily due to presystemic metabolism and partly due to incomplete absorption.
17%
- Numeric value
- 17
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64efe12a-cc43-47e6-b3dc-21dab6ddae06 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7a5deb9-5de4-4a70-bb87-a40084b46f48 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:559cca31-c0d2-45bf-999d-e92fc49a4a89 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d521807-e5ce-498d-a224-5534c5ea61fa (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7328ab4f-2985-448d-8724-8f1b55693b41 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:267dadc1-6960-4d8b-88ef-86be9c5f7159 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f63e616b-ae0c-432b-badc-8c45023aa725 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.
87%
- Numeric value
- 87
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:015a5cf9-f246-48bc-b91e-cd730a53d8aa (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following nasal administration of 10 mg TOSYMRA in 73 healthy subjects, the relative bioavailability of TOSYMRA was approximately 87% [90% confidence interval (CI) 82 to 94] of that obtained following 4 mg subcutaneous injection of sumatriptan.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9f682f0-d50a-4fe6-ab1b-e5a7ec27b3a5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following nasal administration of 10 mg TOSYMRA in 73 healthy subjects, the relative bioavailability of TOSYMRA was approximately 87% [90% confidence interval (CI) 82 to 94] of that obtained following 4 mg subcutaneous injection of sumatriptan.
Projected row 1435
- Medicine slug
- sumatriptan
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 87
- Source count
- 59
- Agreement rate
- 0.847458
- Recorded readings
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 50
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 50 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9485cc30-15e8-4b53-876d-db317145474b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85bf8e58-0984-427b-9ed4-7e0df4e444d2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68daf82a-334e-43ca-b4bb-5c66a82f52c8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cba3661-9b16-416b-b0c0-bbb12549d48f (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination : The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27ca3c0-9de0-ff9c-e053-2a95a90ab894 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:082d05f6-3850-0fa2-e063-6294a90a0c66 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2efd4269-5657-9669-e063-6394a90a583a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e90b0eea-c424-4f00-98da-6ed6e80de1f6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abbd2168-1523-4eb6-a75c-dc4d7d1b1c9b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination: The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2e7d756-1e12-462a-a43f-a9d860b11ee8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf9fd9fe-095b-4478-bd2e-a5534af07761 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352d2ab3-d2c7-48c8-bcd4-d46ed9bdfa85 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac80d018-6abf-2e41-ddea-90b4ff9e9013 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584abe73-8290-4484-ff8e-5890831c095e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:121e36fb-471b-4318-bc47-b087ad68c6f7 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination : The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1042b91c-715c-4e90-b9cc-d91a17f9f7cb (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination: The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aab8786-b225-833a-e063-6394a90ac7ae (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84bfc4ba-4172-4adb-b963-4e0eb438c07a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8c4bbfb-1586-4610-e053-6394a90a8f09 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c87cf537-9f7f-400e-ac4b-86e6f7e78775 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62ba6fef-467a-4500-993c-51907f12a67c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d1f3de0-684a-4092-be30-aa325ff20d04 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d556563f-ad71-45c1-829a-cc11983bce0c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97016a59-3b49-4134-85aa-8c866f285601 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b297a466-7d24-9ebd-e053-2a95a90af4d1 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:284ee7ac-759e-b592-e063-6394a90a78ba (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff08b9ee-03bf-4f5b-930e-233a3b8866af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77f9f135-e840-48f0-81e8-73e08433e768 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baf37e8c-d414-4ca7-a366-97dc202372ff (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efb7ec4e-0a5d-2aae-e053-2a95a90aebf2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c907a3-9624-f893-e053-6294a90a31af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2503fff-c978-4efa-b1b4-d7740b6b26f2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d071aef6-a5bd-4f68-ba6d-03004466897c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a118cf-2179-572a-e053-2995a90acbb0 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85295be9-852d-4e21-e053-2991aa0a8a78 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da77dfc4-551c-4e0e-a65e-cb478f193cd9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d2cd01c-05e7-44cf-a71d-0f474e826b7e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73c9ac06-b55e-41e0-90ec-deb250f37eb5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9c78ac5-7328-4204-8f66-96606d7db5c3 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c95873-576d-a1c2-e053-6294a90a3ff9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f4d487a-c5f7-4707-976b-64e738c98d45 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe09fab6-b9e3-469c-9a38-bcc343dcc899 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination: The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:790acc89-81b3-4869-92e7-dc9f7fa6567b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b9a0ab5-d8bd-4cae-b86c-45740ee1015a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bf70380-8272-4c0d-8841-d39ef2772351 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a41cca-02d2-4b84-975e-d1925f0fca80 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b16886d0-224b-4d83-85c4-bc3eb3606c17 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54c6f8f4-5466-3988-e054-00144ff8d46c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination: The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a96f37d-03f6-678c-e063-6394a90ae0c6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan is approximately 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7628caf4-5272-4e42-e053-2a91aa0a2f24 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The elimination half-life of sumatriptan is approximately 2.5 hours.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64efe12a-cc43-47e6-b3dc-21dab6ddae06 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7a5deb9-5de4-4a70-bb87-a40084b46f48 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:559cca31-c0d2-45bf-999d-e92fc49a4a89 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d521807-e5ce-498d-a224-5534c5ea61fa (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7328ab4f-2985-448d-8724-8f1b55693b41 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:267dadc1-6960-4d8b-88ef-86be9c5f7159 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination : The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f63e616b-ae0c-432b-badc-8c45023aa725 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection.
2.44 ± 1.00 hours
- Numeric value
- 2.44
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:015a5cf9-f246-48bc-b91e-cd730a53d8aa (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan following administration of TOSYMRA is 2.44 ± 1.00 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9f682f0-d50a-4fe6-ab1b-e5a7ec27b3a5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Elimination The elimination half-life of sumatriptan following administration of TOSYMRA is 2.44 ± 1.00 hours.
Projected row 1436
- Medicine slug
- sumatriptan
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 87
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
14%
- Numeric value
- 14
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68daf82a-334e-43ca-b4bb-5c66a82f52c8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Plasma protein binding is low (14% to 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9c78ac5-7328-4204-8f66-96606d7db5c3 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Plasma protein binding is low (14% to 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a41cca-02d2-4b84-975e-d1925f0fca80 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Plasma protein binding is low (14% to 21%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7628caf4-5272-4e42-e053-2a91aa0a2f24 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Plasma protein binding is low (14% to 21%).
Projected row 1437
- Medicine slug
- sumatriptan
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 87
- Source count
- 50
- Agreement rate
- 1
- Recorded readings
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 50
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 50 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9485cc30-15e8-4b53-876d-db317145474b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85bf8e58-0984-427b-9ed4-7e0df4e444d2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68daf82a-334e-43ca-b4bb-5c66a82f52c8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the t max is slightly later during the attack, approximately 2.5 hours compared to 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cba3661-9b16-416b-b0c0-bbb12549d48f (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27ca3c0-9de0-ff9c-e053-2a95a90ab894 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The Cmax is similar during a migraine attack and during a migraine‑free period, but the Tmax is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:082d05f6-3850-0fa2-e063-6294a90a0c66 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2efd4269-5657-9669-e063-6394a90a583a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e90b0eea-c424-4f00-98da-6ed6e80de1f6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abbd2168-1523-4eb6-a75c-dc4d7d1b1c9b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2e7d756-1e12-462a-a43f-a9d860b11ee8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf9fd9fe-095b-4478-bd2e-a5534af07761 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352d2ab3-d2c7-48c8-bcd4-d46ed9bdfa85 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac80d018-6abf-2e41-ddea-90b4ff9e9013 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584abe73-8290-4484-ff8e-5890831c095e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:121e36fb-471b-4318-bc47-b087ad68c6f7 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1042b91c-715c-4e90-b9cc-d91a17f9f7cb (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aab8786-b225-833a-e063-6394a90ac7ae (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84bfc4ba-4172-4adb-b963-4e0eb438c07a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8c4bbfb-1586-4610-e053-6394a90a8f09 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The Cmax is similar during a migraine attack and during a migraine-free period, but the Tmax is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c87cf537-9f7f-400e-ac4b-86e6f7e78775 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62ba6fef-467a-4500-993c-51907f12a67c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d1f3de0-684a-4092-be30-aa325ff20d04 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d556563f-ad71-45c1-829a-cc11983bce0c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97016a59-3b49-4134-85aa-8c866f285601 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b297a466-7d24-9ebd-e053-2a95a90af4d1 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:284ee7ac-759e-b592-e063-6394a90a78ba (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The Cmax is similar during a migraine attack and during a migraine‑free period, but the Tmax is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff08b9ee-03bf-4f5b-930e-233a3b8866af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77f9f135-e840-48f0-81e8-73e08433e768 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baf37e8c-d414-4ca7-a366-97dc202372ff (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efb7ec4e-0a5d-2aae-e053-2a95a90aebf2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The Cmax is similar during a migraine attack and during a migraine‑free period, but the Tmax is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c907a3-9624-f893-e053-6294a90a31af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The Cmax is similar during a migraine attack and during a migraine-free period, but the Tmax is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2503fff-c978-4efa-b1b4-d7740b6b26f2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d071aef6-a5bd-4f68-ba6d-03004466897c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a118cf-2179-572a-e053-2995a90acbb0 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The Cmax is similar during a migraine attack and during a migraine-free period, but the Tmax is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85295be9-852d-4e21-e053-2991aa0a8a78 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da77dfc4-551c-4e0e-a65e-cb478f193cd9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d2cd01c-05e7-44cf-a71d-0f474e826b7e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73c9ac06-b55e-41e0-90ec-deb250f37eb5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9c78ac5-7328-4204-8f66-96606d7db5c3 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the t max is slightly later during the attack, approximately 2.5 hours compared to 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c95873-576d-a1c2-e053-6294a90a3ff9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The Cmax is similar during a migraine attack and during a migraine-free period, but the Tmax is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f4d487a-c5f7-4707-976b-64e738c98d45 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe09fab6-b9e3-469c-9a38-bcc343dcc899 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:790acc89-81b3-4869-92e7-dc9f7fa6567b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b9a0ab5-d8bd-4cae-b86c-45740ee1015a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine‑free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bf70380-8272-4c0d-8841-d39ef2772351 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a41cca-02d2-4b84-975e-d1925f0fca80 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the t max is slightly later during the attack, approximately 2.5 hours compared to 2.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b16886d0-224b-4d83-85c4-bc3eb3606c17 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54c6f8f4-5466-3988-e054-00144ff8d46c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a96f37d-03f6-678c-e063-6394a90ae0c6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the T max is slightly later during the attack, approximately 2.5 hours compared with 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7628caf4-5272-4e42-e053-2a91aa0a2f24 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The C max is similar during a migraine attack and during a migraine-free period, but the t max is slightly later during the attack, approximately 2.5 hours compared to 2.0 hours.
Projected row 1438
- Medicine slug
- sumatriptan
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 87
- Source count
- 87
- Agreement rate
- 0.609195
- Recorded readings
2.7 L/kg
- Numeric value
- 2.7
- Unit
- L/kg
- Source records
- 53
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 53 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9485cc30-15e8-4b53-876d-db317145474b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85bf8e58-0984-427b-9ed4-7e0df4e444d2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64efe12a-cc43-47e6-b3dc-21dab6ddae06 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5cba3661-9b16-416b-b0c0-bbb12549d48f (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f27ca3c0-9de0-ff9c-e053-2a95a90ab894 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:082d05f6-3850-0fa2-e063-6294a90a0c66 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2efd4269-5657-9669-e063-6394a90a583a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e90b0eea-c424-4f00-98da-6ed6e80de1f6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7a5deb9-5de4-4a70-bb87-a40084b46f48 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abbd2168-1523-4eb6-a75c-dc4d7d1b1c9b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2e7d756-1e12-462a-a43f-a9d860b11ee8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf9fd9fe-095b-4478-bd2e-a5534af07761 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352d2ab3-d2c7-48c8-bcd4-d46ed9bdfa85 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:559cca31-c0d2-45bf-999d-e92fc49a4a89 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d521807-e5ce-498d-a224-5534c5ea61fa (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac80d018-6abf-2e41-ddea-90b4ff9e9013 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584abe73-8290-4484-ff8e-5890831c095e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:121e36fb-471b-4318-bc47-b087ad68c6f7 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1042b91c-715c-4e90-b9cc-d91a17f9f7cb (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aab8786-b225-833a-e063-6394a90ac7ae (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84bfc4ba-4172-4adb-b963-4e0eb438c07a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8c4bbfb-1586-4610-e053-6394a90a8f09 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c87cf537-9f7f-400e-ac4b-86e6f7e78775 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62ba6fef-467a-4500-993c-51907f12a67c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d1f3de0-684a-4092-be30-aa325ff20d04 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d556563f-ad71-45c1-829a-cc11983bce0c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97016a59-3b49-4134-85aa-8c866f285601 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b297a466-7d24-9ebd-e053-2a95a90af4d1 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:284ee7ac-759e-b592-e063-6394a90a78ba (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff08b9ee-03bf-4f5b-930e-233a3b8866af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77f9f135-e840-48f0-81e8-73e08433e768 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baf37e8c-d414-4ca7-a366-97dc202372ff (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efb7ec4e-0a5d-2aae-e053-2a95a90aebf2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c907a3-9624-f893-e053-6294a90a31af (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2503fff-c978-4efa-b1b4-d7740b6b26f2 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d071aef6-a5bd-4f68-ba6d-03004466897c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1a118cf-2179-572a-e053-2995a90acbb0 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85295be9-852d-4e21-e053-2991aa0a8a78 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da77dfc4-551c-4e0e-a65e-cb478f193cd9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d2cd01c-05e7-44cf-a71d-0f474e826b7e (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7328ab4f-2985-448d-8724-8f1b55693b41 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73c9ac06-b55e-41e0-90ec-deb250f37eb5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c95873-576d-a1c2-e053-6294a90a3ff9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f4d487a-c5f7-4707-976b-64e738c98d45 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe09fab6-b9e3-469c-9a38-bcc343dcc899 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:267dadc1-6960-4d8b-88ef-86be9c5f7159 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:790acc89-81b3-4869-92e7-dc9f7fa6567b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b9a0ab5-d8bd-4cae-b86c-45740ee1015a (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bf70380-8272-4c0d-8841-d39ef2772351 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b16886d0-224b-4d83-85c4-bc3eb3606c17 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54c6f8f4-5466-3988-e054-00144ff8d46c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a96f37d-03f6-678c-e063-6394a90ae0c6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f63e616b-ae0c-432b-badc-8c45023aa725 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.7 L/kg.
50 ± 8 liters
- Numeric value
- 50
- Unit
- L
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b1bb8c9-be3a-47c3-b3bc-9c983cde7d23 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e5b104f-2b9e-416e-92fb-ef1bdaea867d (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f42c6e00-e693-48f3-8e84-c3f139e1adf5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65147b04-0b6b-4d30-9710-d5cdce85e8f5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f34f450-d6f3-49a8-b55a-8e1e4a9ee950 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:015a5cf9-f246-48bc-b91e-cd730a53d8aa (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d13df081-648c-44c0-9854-5a1bfe23ae89 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half‑life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c62307-bd19-4418-b1b0-c0274b5595df (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44d6d757-489c-4262-a518-af8c470734d6 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:587e6bb5-a665-4396-814e-ce893a20290b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e8b65f7-9d3b-42f2-8d7e-69b143365980 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9f682f0-d50a-4fe6-ab1b-e5a7ec27b3a5 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e26764d-ce26-e5ac-e6db-0f1f7a1d5c2b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c009976a-4e29-4aeb-9e55-a88766ebb1fb (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f235152e-dd8d-4679-9d9f-404fe5ff4fba (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4996682c-cd85-6e39-e063-6294a90a90ae (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b4915d3-be7a-e5fa-e063-6294a90a7f98 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16b7e44d-afa0-4177-80ef-c3ae9a78a4e1 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1909558d-8342-4af0-9487-eecdaac70070 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fef1176-7a38-eca3-22ca-83efe5ca6620 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f675d0db-f356-4eda-be62-b00af476326c (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b183c7ba-2cc6-4854-a9a6-71ccd3592586 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eb49807-fa9d-4a0d-9a3c-76de5b23b01b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01293e09-d49a-411d-9647-6f23318ac201 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fee7d073-0b99-48f2-7985-0d8cf970894b (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half‑life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b417f8c-9e5b-45a1-b8af-183818258df9 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4240c6e-6b9e-405f-82e6-a3d5bd9e6f29 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38fd19bf-b7aa-812c-8a74-2414dfec45f4 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d3602a1-1cd5-41c2-a0a3-3d20e90a92fa (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15± 2 minutes.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:865865ca-01df-4815-aa7e-2dfadc2c539d (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
Following a 6 mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half-life was 15 ± 2 minutes.
2.4 L/kg
- Numeric value
- 2.4
- Unit
- L/kg
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68daf82a-334e-43ca-b4bb-5c66a82f52c8 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9c78ac5-7328-4204-8f66-96606d7db5c3 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77a41cca-02d2-4b84-975e-d1925f0fca80 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.4 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7628caf4-5272-4e42-e053-2a91aa0a2f24 (opens source in a new tab)
Sumatriptan label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 2.4 L/kg.
Projected row 1439
- Medicine slug
- suzetrigine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0976da4-1d20-4517-945c-b60ed2f41c12 (opens source in a new tab)
Suzetrigine label
Version not recorded · Effective date not recorded
Mean (CV%) Apparent Volume of Distribution, L 495 (25.0%) NA Protein Binding 99% 96% Elimination Mean (CV%) Effective Half-Life, hours 23.6 (36.2%) 33.0 (34.9%) Steady State Mean (CV%) Apparent Oral Clearance, L/hours 13.9 (37.5%) NA Metabolism Primary Pathway CYP3A CYP3A Excretion Primary Pathway Feces: 49.9% (9.1% SUZ and rest as metabolites) Urine: 44.0% (primarily as metabolites) Effect of Foo
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d229cf71-96ec-4206-960b-d56fafc250ac (opens source in a new tab)
Suzetrigine label
Version not recorded · Effective date not recorded
Mean (CV%) Apparent Volume of Distribution, L 495 (25.0%) NA Protein Binding 99% 96% Elimination Mean (CV%) Effective Half-Life, hours 23.6 (36.2%) 33.0 (34.9%) Steady State Mean (CV%) Apparent Oral Clearance, L/hours 13.9 (37.5%) NA Metabolism Primary Pathway CYP3A CYP3A Excretion Primary Pathway Feces: 49.9% (9.1% SUZ and rest as metabolites) Urine: 44.0% (primarily as metabolites) Effect of Foo
Projected row 1440
- Medicine slug
- suzetrigine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0976da4-1d20-4517-945c-b60ed2f41c12 (opens source in a new tab)
Suzetrigine label
Version not recorded · Effective date not recorded
The median T max of suzetrigine and M6-SUZ in the fasted state was 3 hours and 8 to 10 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d229cf71-96ec-4206-960b-d56fafc250ac (opens source in a new tab)
Suzetrigine label
Version not recorded · Effective date not recorded
The median T max of suzetrigine and M6-SUZ in the fasted state was 3 hours and 8 to 10 hours, respectively.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1430Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.